The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection: Two Randomized Controlled Trials
Abstract
CONTEXT: In the last 3 decades, herpes simplex virus type 2 (HSV-2) infection seroprevalence and neonatal herpes have increased substantially. An effective vaccine for the prevention of genital herpes could help control this epidemic. OBJECTIVE: To evaluate the efficacy of a vaccine for prevention of HSV-2 infection. DESIGN: Two randomized, double-blind, placebo-controlled multicenter trials of a recombinant subunit vaccine containing 30 microg each of 2 major HSV-2 surface glycoproteins (gB2 and gD2) against which neutralizing antibodies are directed, administered at months 0, 1, and 6. Control subjects were given a citrate buffer vehicle. Participants were followed up for 1 year after the third immunization. SETTING AND PARTICIPANTS: We enrolled 2393 persons from December 10, 1993, to April 4, 1995, who were HSV-2 and human immunodeficiency virus seronegative. One trial with 18 centers enrolled 531 HSV-2-seronegative partners of HSV-2-infected persons; the other, with 22 centers, enrolled 1862 persons attending sexually transmitted disease clinics. A total of 2268 (94.8%) met inclusion criteria and were included in the analysis with 1135 randomized to placebo and 2012 to vaccine. MAIN OUTCOME MEASURE: Time to acquisition of HSV-2 infection, defined by seroconversion or isolation of HSV-2 in culture during the study period by randomization group. RESULTS: Time-to-event curves indicated a 50% lower acquisition rate among vaccine vs placebo recipients during the initial 5 months of the trial; however, overall vaccine efficacy was 9% (95% confidence interval, -29% to 36%). Acquisition rates of HSV-2 were 4.6 and 4.2 per 100 patient-years in the placebo and vaccine recipients, respectively (P =.58). Follow-up of vaccine recipients acquiring HSV-2 infection showed vaccination had no significant influence on duration of clinical first genital HSV-2 episodes (vaccine, median of 7.1 days; placebo, 6.5 days; P>.10) or subsequent frequency of reactivation (median monthly recurrence rate with vaccine, 0.2; with placebo, 0.3; P>.10). The vaccine induced high levels of HSV-2-specific neutralizing antibodies in vaccinated persons who did and did not develop genital herpes. CONCLUSIONS: Efficient and sustained protection from sexual acquisition of HSV-2 infection will require more than high titers of specific neutralizing antibodies. Protection against sexually transmitted viruses involving exposure over a prolonged period will require a higher degree of vaccine efficacy than that achieved in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 26,755
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Applied Regression Analysis and Other Multivariable Methods
Walker, E. (1989) · Technometrics · doi:10.1080/00401706.1989.10488486 · Cited by 8,538
The Design and Analysis of Clinical Experiments
Fleiss, J. L. (1999) · Wiley eBooks · doi:10.1002/9781118032923 · Cited by 4,819
Counting Processes and Survival Analysis.
Dabrowska, D. M., Fleming, T. R., & Harrington, D. P. (1992) · Journal of the American Statistical Association · doi:10.2307/2290673 · Cited by 2,271
Wasserheit, J. N. (1992) · PubMed · Cited by 1,245
Herpes Simplex Virus Type 2 in the United States, 1976 to 1994
Fleming, D. T., McQuillan, G. M., Johnson, R. E., Nahmias, A. J., Aral, S. O., Lee, F. K., & St. Louis, M. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371601 · Cited by 1,189
Genital Herpes Simplex Virus Infections: Clinical Manifestations, Course, and Complications
COREY, L., ADAMS, H. G., BROWN, Z. A., & HOLMES, K. K. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-6-958 · Cited by 931
Self-citationThe Acquisition of Herpes Simplex Virus during Pregnancy
Brown, Z. A., Selke, S., Zeh, J., Kopelman, J., Maslow, A., Ashley, R. L., Watts, D. H., Berry, S., Herd, M., & Corey, L. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708213370801 · Cited by 782
Self-citationSero-epidemiological and -sociological patterns of herpes simplex virus infection in the world.
Nahmias, A. J., Lee, F. K., & Beckman-Nahmias, S. (1990) · PubMed · Cited by 531
Virologic Characteristics of Subclinical and Symptomatic Genital Herpes Infections
Wald, A., Zeh, J., Selke, S., Ashley, R. L., & Corey, L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509213331205 · Cited by 507
Self-citationRisk Factors for the Sexual Transmission of Genital Herpes
Mertz, G. J., Benedetti, J., Ashley, R., Selke, S. A., & Corey, L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-3-197 · Cited by 475
Self-citationLachin, J. M., & Foulkes, M. A. (1986) · Biometrics · doi:10.2307/2531201 · Cited by 400
Wald, A., Corey, L., Cone, R., Hobson, A., Davis, G., & Zeh, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119237 · Cited by 388
Self-citationPrior Herpes Simplex Virus Type 2 Infection as a Risk Factor for HIV Infection
Holmberg, S. D. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03720070048033 · Cited by 367
Prober, C. G., Sollender, W. M., Yasukawa, L. L., Au, D. S., Yeager, A. S., & Arvin, A. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701293160503 · Cited by 339
Frequent Recovery of HIV-1 From Genital Herpes Simplex Virus Lesions in HIV-1–Infected Men
Schacker, T. (1998) · JAMA · doi:10.1001/jama.280.1.61 · Cited by 309
Effects on Infants of a First Episode of Genital Herpes during Pregnancy
Brown, Z. A., Vontver, L. A., Benedetti, J., Critchlow, C. W., Sells, C. J., Berry, S., & Corey, L. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172002 · Cited by 299
Self-citationMERTS, G. J., SCHMIDT, O., JOURDEN, J. L., GUINAN, M. E., REMINGTON, M. L., FAHBLANDER, A., WINTER, C., HOLMES, K. K., & COREY, L. (1985) · Sexually Transmitted Diseases · doi:10.1097/00007435-198501000-00007 · Cited by 255
Self-citationA Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy
Langenberg, A. G. M., Burke, R. L., Adair, S. F., Sekulovich, R., Tigges, M., Dekker, C. L., & Corey, L. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-12-199506150-00001 · Cited by 177
Self-citationRelationship of Antibody to Outcome in Neonatal Herpes Simplex Virus Infections
Yeager, A. S., Arvin, A. M., Urbani, L. J., & Kemp, J. A. (1980) · Infection and Immunity · doi:10.1128/iai.29.2.532-538.1980 · Cited by 169
Ashley, R. L., Cent, A., Maggs, V., Nahmias, A. J., & Corey, L. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-7-520 · Cited by 149
Self-citationSiegel, D. (1992) · JAMA · doi:10.1001/jama.268.13.1702 · Cited by 144
MERTZ, G. J., Ashley, R. L., Burke, R. L., Benedetti, J., Critchlow, C. W., JONES, C. C., & Corey, L. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/161.4.653 · Cited by 127
Self-citationBryson, Y. J., Dillon, M., Bernstein, D. I., Radolf, J. D., Zakowski, P. C., & Garratty, E. M. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.4.942 · Cited by 121
Acquisition of Genital Herpes from an Asymptomatic Sexual Partner
Rooney, J. F., Felser, J. M., Ostrove, J. M., & Straus, S. E. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142407 · Cited by 115
Self-citationSample size and power determination for stratified clinical trials
Bernstein, D., & Lagakos, S. W. (1978) · Journal of Statistical Computation and Simulation · doi:10.1080/00949657808810249 · Cited by 90
Herpes simplex virus type 2 antibody in patients attending antenatal or STD clinics
Cunningham, A. L., Lee, F. K., Ho, D. W. T., Field, P. R., Law, C. L. H., Packham, D. R., McCrossin, I. D., Sjögren‐Jansson, E., Jeansson, S. L., & Nahmias, A. J. (1993) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1993.tb121867.x · Cited by 70
Reinfection is an Uncommon Occurrence in Patients with Symptomatic Recurrent Genital Herpes
Schmidt, O. W., Fife, K. H., & Corey, L. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/149.4.645 · Cited by 63
Self-citationContemporary Approaches to Vaccination Against Herpes Simplex Virus
Burke, R. L. (1992) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-77247-4_9 · Cited by 53
Self-citationDalessio, J., & Ashley, R. L. (1992) · Journal of Clinical Microbiology · doi:10.1128/jcm.30.4.1005-1007.1992 · Cited by 43
Self-citationLakeman, A. D., Nahmias, A. J., & Whitley, R. J. (1986) · Sexually Transmitted Diseases · doi:10.1097/00007435-198604000-00001 · Cited by 39
Terhune, S. S., Coleman, K. T., Sekulovich, R. E., Burke, R. L., & Spear, P. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/515590 · Cited by 36
Self-citation
Cited by
Herpes simplex virus infections
Whitley, R. J., & Roizman, B. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04638-9 · Cited by 1,366
Whitley, R. J., Kimberlin, D. W., & Roizman, B. (1998) · Clinical Infectious Diseases · doi:10.1086/514600 · Cited by 1,149
The Xs and Y of immune responses to viral vaccines
Klein, S. L., Jedlicka, A., & Pekosz, A. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70049-9 · Cited by 815
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, F. Y., Slaoui, M., Denis, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011915 · Cited by 794
Self-citationHow sex and age affect immune responses, susceptibility to infections, and response to vaccination
Giefing‐Kröll, C., Berger, P., Lepperdinger, G., & Grubeck‐Loebenstein, B. (2015) · Aging Cell · doi:10.1111/acel.12326 · Cited by 761
Metadata
- Authors
- Corey, L., Langenberg, A. G. M., Ashley, R., Sekulovich, R. E., Izu, A. E., Douglas, Jr., Handsfield, H. H., Warren, T., Marr, L., Tyring, S., DiCarlo, R., Adimora, A. A., Leone, P., Dekker, C. L., Burke, R. L., Leong, W. P., Straus, S. E., & for the Chiron HSV Vaccine Study Group
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1999-07-28
- Volume
- 282
- Issue
- 4
- Pages
- 331-40
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2156555210
- Cited by
- 490
- References
- 34
- FWCI
- 17.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.